

UNITED THERAPEUTICS CORP

Form 8-K

March 15, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 15, 2004

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware

000-26301

52-1984749

(State or Other
Jurisdiction of
Incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification Number)

1110 Spring Street
Silver Spring, MD

20910

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

(301) 608-9292

Item 5. Other Events.

On March 15, 2004, United Therapeutics Corporation issued a press release announcing that its Chief Financial Officer Fred Hadeed and its General Counsel Paul Mahon have each adopted pre-arranged stock trading plans under Securities and Exchange Commission Rule 10b5-1 to sell a portion of their company stock over three years as part of their individual long-term strategy for asset diversification and liquidity. In addition, Bina Aspen Rothblatt, the spouse of Chief Executive Officer Martine Rothblatt, has also adopted a three-year Rule 10b5-1 stock trading plan.

Item 7. Exhibits

(c) Exhibits

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99	Press release dated March 15, 2004

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 15, 2004

UNITED THERAPEUTICS
CORPORATION

By: /s/ Paul A. Mahon

Name: Paul A. Mahon

Title: General Counsel

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99	Press release dated March 15, 2004